Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126,803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Zhang W, et al. Among authors: wang h, wang f, wang z, wang y. J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366. J Immunother Cancer. 2023. PMID: 37730273 Free PMC article. Clinical Trial.
Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.
Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R, Ma G. Wang G, et al. Among authors: wang z, wang r. Front Immunol. 2023 May 22;14:1219757. doi: 10.3389/fimmu.2023.1219757. eCollection 2023. Front Immunol. 2023. PMID: 37283748 Free PMC article.
126,803 results
You have reached the last available page of results. Please see the User Guide for more information.